1. 首页
  2. 产品目录

LY2228820,新型有效的p38 MAPK抑制剂

LY2228820 （订货以英文为准）

编号：L127430
CAS号：862507-23-1
分子式：C25H33FN6O3S
分子量：516.63
货号 品牌 包装 目录价 您的价格 库存 数量 购买
L127430-25mg 阿拉丁 25mg ¥428.90
请登录
L127430-5mg 阿拉丁 5mg ¥357.90
请登录
L127430-50mg 阿拉丁 50mg ¥635.90
请登录
产品名称 LY2228820
中文名称 LY2228820,新型有效的p38 MAPK抑制剂
CAS号 862507-23-1
分子式（M.F.） C25H33FN6O3S
分子量（M.W.） 516.63
储存条件 -20°C储存
溶解性DMSO ≥33mg/mL Water ≥121mg/mL Ethanol ≥2.6mg/mL
存贮条件储存温度-20°C
应用A p38 MAP Kinase inhibitor with IC50 of 70nM
产品介绍LY2228820是p38MAPK抑制剂，对p38αMAPK和p38βMAPK的IC50分别为7 nM和3 nM。
生化机理SB 202190 is a p38 MAP (mitogen activated protein) Kinase inhibitor with an IC50 of 7 nm. LY2228820 inhibits lipopolysaccharide (LPS)-induced TNFα formation in murine peritoneal macrophages, with IC50 of 5.2 nM. In multiple myeloma (MM) cells, LY2228820 significantly blocks p38MAPK signaling, as revealed by its inhibition on phosphorylation of HSP27, a downstream target of p38MAPK, without affecting the expression level of HSP27. LY2228820 enhances bortezomib-induced cytotoxicity and apoptosis, but it alone doesn't inhibit the growth of MM.1S cells. LY2228820 also inhibits secretion of IL-6 and MIP-1α in long-term BM stromal cells (LT-BMSCs), BM mononuclear cells (BMMNCs), peripheral blood (PB) CD138+, CD138? or PB CD14+ cells. LY2228820 also blocks osteoclastogenesis from CD14+ cells.
别名LY 2228820;LY-2228820;5-[2-(叔丁基)-4-(4-氟苯基)-1H-咪唑-5-基]-3-(2,2-二甲基丙基)-3H-咪唑并[4,5-b]吡啶-2-胺二甲磺酸盐;Ralimetinib dimesylate；LY2228820 dimesylate;LY2228820 2MsOH;LY 2228820;LY-2228820；5-[2-(tert-Butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate
标识符号https://www.aladdin-e.com/images/ghs/ghs05.jpg,https://www.aladdin-e.com/images/ghs/ghs07.jpg
信号词Danger
危害声明H302-H318
警示性声明P280-P305 + P351 + P338
个人防护设备dust mask type N95 (US), Eyeshields, Gloves
RTECSUS7968332
WGK德国3
搜索质检报告(COA)
搜索MSDS
相关产品